Page last updated: 2024-10-19

nitrates and Chronic Kidney Failure

nitrates has been researched along with Chronic Kidney Failure in 45 studies

Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.

Research Excerpts

ExcerptRelevanceReference
"Proteinuria was significantly lower in L-arginine-treated animals from week 24 onward (p<0."5.32Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure. ( Albrecht, EW; Smit-van Oosten, A; Stegeman, CA; van Goor, H, 2003)
"Patients with essential hypertension (n = 24) were administered a low-salt diet (2 g NaCl/day), a high-salt diet (20-23 g) and then a low-salt diet for 7 days, and plasma levels of nitrate and nitrite (NOx) and asymmetric dimethylarginine (ADMA) were examined."5.10Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease. ( Fujiwara, N; Nakamura, M; Okumura, K; Osanai, T; Osawa, H; Saitoh, M; Sasaki, S; Tomita, H; Yamabe, H, 2002)
"Supplementation with L-arginine (ARG) strikingly ameliorates proteinuria and glomerulosclerosis in remnant rats by overcoming nitric oxide (NO) deficiency."5.09Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure. ( Andreucci, M; Andreucci, VE; Bellizzi, V; Capuano, A; Cianciaruso, B; Corso, G; De Nicola, L; Garibotto, G; Minutolo, R, 1999)
" L-arginine has been used to improve endothelial function by increasing nitric oxide (NO) bioavailability and in animal models this in turn has attenuated the progression of atherosclerosis."2.70Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. ( Bennett-Richards, KJ; Bruckdorfer, KR; Deanfield, JE; Donald, AE; Kattenhorn, M; Oakley, GR; Rees, L; Varghese, Z, 2002)
"In ND and HD, reactive hyperemia as well as %NTG and %FMD were attenuated to a similar degree."2.70Impairment of vascular responses to reactive hyperemia and nitric oxide in chronic renal failure. ( Hiraoka, K; Inoue, T; Ishigami, Y; Izumi, M; Nakanishi, T; Otaki, Y; Takamitsu, Y, 2002)
"We hypothesized that in patients with chronic renal failure, a condition associated with both hyperhomocysteinemia and atherosclerosis, treatment with folic acid would improve endothelial function."2.69Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? ( Jones, HJ; Landray, MJ; McGlynn, FJ; Thambyrajah, J; Townend, JN; Wheeler, DC, 2000)
"FE(NO )values of ESRD patients were similar to normals, while EBC-NOx, NO2-, NH3+ and pH were significantly higher in ESRD patients compared to normals (EBC-NOx 12."1.35Breath analysis in patients with end-stage renal disease: effect of haemodialysis. ( Bagnis, C; Bommarito, L; Bruno, M; Bugiani, M; Ferrero, N; Guida, G; Heffler, E; Petrarulo, M; Rolla, G, 2008)
"Proteinuria was significantly lower in L-arginine-treated animals from week 24 onward (p<0."1.32Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure. ( Albrecht, EW; Smit-van Oosten, A; Stegeman, CA; van Goor, H, 2003)
"Patients with ADPKD have defective nitric oxide generation from diminished cNOS activity."1.32Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. ( Iversen, J; Strandgaard, S; Wang, D; Wilcox, CS, 2003)
"Whether rHuEpo treatment in ESRD is accompanied by alterations in NO production was explored in patients undergoing hemodialysis."1.31Biphasic changes in nitric oxide generation in hemodialyzed patients with end-stage renal disease treated with recombinant human erythropoietin. ( Acchiardo, SR; Cardenas, R; Kang, ES; Mishra, S; Tevlin, MT; Wang, YB, 2000)
"Patients with chronic renal failure had a higher exhaled nitric oxide concentration [39+/-3 versus 19+/-1 parts per billion, (mean+/-S."1.30Increased excretion of nitric oxide in exhaled air of patients with chronic renal failure. ( Hirata, Y; Kakoki, M; Matsumoto, A; Momomura, Si; Nagata, D; Omata, M; Sugimoto, T; Tagawa, H, 1999)
"It is concluded that chronic renal failure in rats is a low nitric oxide production state."1.29Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. ( Ashab, I; Blum, M; Cabili, S; Chernihovsky, T; Hassner, A; Iaina, A; Peer, G; Schwartz, D; Silverberg, D; Wollman, Y, 1995)

Research

Studies (45)

TimeframeStudies, this research(%)All Research%
pre-19902 (4.44)18.7374
1990's10 (22.22)18.2507
2000's27 (60.00)29.6817
2010's4 (8.89)24.3611
2020's2 (4.44)2.80

Authors

AuthorsStudies
Heredia Martinez, A1
Rosa Diez, G1
Ferraris, V1
Coccia, PA1
Ferraris, JR1
Checa, A1
Wheelock, CE1
Lundberg, JO1
Weitzberg, E1
Carlström, M1
Krmar, RT1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y7
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L3
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J4
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S2
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D2
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Anand, S1
Staniec, A1
Montez-Rath, M1
Vlahos, P1
Manivannan, J1
Balamurugan, E1
Silambarasan, T1
Raja, B1
Rolla, G1
Bruno, M1
Bommarito, L1
Heffler, E1
Ferrero, N1
Petrarulo, M1
Bagnis, C1
Bugiani, M1
Guida, G1
Zhang, DL1
Liao, H1
Wei, YY1
Zhang, QD1
Wang, ZG1
Mikulić, I1
Petrik, J1
Galesić, K1
Romić, Z1
Cepelak, I1
Zeljko-Tomić, M1
Oner-Iyidogan, Y1
Gurdol, F1
Kocak, H1
Oner, P1
Cetinalp-Demircan, P1
Caliskan, Y1
Kocak, T1
Turkmen, A2
Akbasli, AC1
Keven, K1
Erbay, B1
Nebioglu, S1
Wagner, L1
Riggleman, A1
Erdely, A1
Couser, W1
Baylis, C3
Zhou, XJ1
Vaziri, ND2
Wang, HW1
Wang, XQ1
Osanai, T1
Fujiwara, N1
Saitoh, M1
Sasaki, S1
Tomita, H1
Nakamura, M1
Osawa, H1
Yamabe, H1
Okumura, K1
Bennett-Richards, KJ1
Kattenhorn, M1
Donald, AE1
Oakley, GR1
Varghese, Z1
Bruckdorfer, KR1
Deanfield, JE1
Rees, L1
Nakanishi, T1
Ishigami, Y1
Otaki, Y1
Izumi, M1
Hiraoka, K1
Inoue, T1
Takamitsu, Y1
Albrecht, EW1
van Goor, H1
Smit-van Oosten, A1
Stegeman, CA1
Iversen, J1
Wilcox, CS1
Strandgaard, S1
Migliacci, R1
Falcinelli, F1
Imperiali, P1
Floridi, A1
Nenci, GG1
Gresele, P1
Lele, PS1
Dunn, SR1
Simenhoff, ML1
Fiddler, W1
Pensabene, JW1
Ashab, I1
Peer, G2
Blum, M2
Wollman, Y2
Chernihovsky, T2
Hassner, A1
Schwartz, D2
Cabili, S1
Silverberg, D2
Iaina, A2
Yang, CW1
Hwang, TL1
Wu, CH1
Lai, PC1
Huang, JY1
Yu, CC1
Shyr, MH1
Huang, CC1
Nosrati, S1
Campese, VM1
Fukuyama, N1
Takebayashi, Y1
Hida, M1
Ishida, H1
Ichimori, K1
Nakazawa, H1
Tsukada, T1
Yokoyama, K1
Arai, T1
Takemoto, F1
Hara, S1
Yamada, A1
Kawaguchi, Y1
Hosoya, T1
Igari, J1
Nishimura, M2
Takahashi, H2
Maruyama, K1
Ohtsuka, K1
Nanbu, A1
Hara, K1
Yoshimura, M2
Matsumoto, A1
Hirata, Y1
Kakoki, M1
Nagata, D1
Momomura, Si1
Sugimoto, T1
Tagawa, H1
Omata, M1
Schmidt, RJ2
Yokota, S1
Tracy, TS1
Sorkin, MI1
De Nicola, L1
Bellizzi, V1
Minutolo, R1
Andreucci, M1
Capuano, A1
Garibotto, G1
Corso, G1
Andreucci, VE1
Cianciaruso, B1
Barak, N1
Zemel, R1
Ben-Ari, Z1
Braun, M1
Tur-Kaspa, R1
Cases, A1
Esforzado, N1
Lario, S1
Vera, M1
Lopez-Pedret, J1
Rivera-Fillat, F1
Jimenez, W1
Kang, ES2
Wang, YB1
Cardenas, R1
Tevlin, MT2
Mishra, S1
Acchiardo, SR2
Kim, SW2
Lee, J2
Kang, DG2
Jung, K1
Kim, NH1
Suh, SP1
Choi, KC2
Kang, YJ1
Hon, WM1
Lee, JC1
Lee, KH1
Wolf, WC1
Yoshida, H1
Agata, J1
Chao, L1
Chao, J1
Smith, SD1
Wheeler, MA1
Lorber, MI1
Weiss, RM1
Thambyrajah, J1
Landray, MJ1
McGlynn, FJ1
Jones, HJ1
Wheeler, DC1
Townend, JN1
Clermont, G1
Lecour, S1
Lahet, J1
Siohan, P1
Vergely, C1
Chevet, D1
Rifle, G1
Rochette, L1
Paek, YW1
Miles, DE1
Cates, TB1
Cantaro, S1
Milan Manani, S1
Marcon, R1
Bonfante, L1
Masiero, M1
D'Angelo, A1
Calò, L1
Itzhakov, E1
Grosskopf, I1
Segev, D1
Ni, Z1
Oveisi, F1
Liang, K1
Pandian, R1
Erdoğan, C1
Unlüçerçi, Y1
Kuru, A1
Cetin, O1
Bekpinar, S1
Klütsch, K1
Grosswendt, J1
Scheitza, E1
Heidland, A1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients[NCT01157234]Phase 432 participants (Actual)Interventional2010-07-31Completed
Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant[NCT01239472]Phase 430 participants (Actual)Interventional2011-01-31Completed
Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720]Phase 2120 participants (Actual)Interventional2005-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Diastolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups

Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury). (NCT01157234)
Timeframe: Change in Baseline, Month-12

Interventionmillimeter, mercury (Least Squares Mean)
Nebivolol-0.66
Metoprolol-2.35

Estimated Glomerular Filtration Rate (ml/Minute) Change From Baseline to Month-12 Between the Groups

The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Interventionpercent change (Least Squares Mean)
Nebivolol2.16
Metoprolol10.43

Mean Arterial Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups

"Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.~Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure" (NCT01157234)
Timeframe: Change in Baseline, Month-12

Interventionmillimeter, Mercury (Least Squares Mean)
Nebivolol-1.07
Metoprolol-3.19

Number of Antihypertensive Drug Classes Change From Baseline to Month-12 Between the Groups.

Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Interventionpercent change (Least Squares Mean)
Nebivolol-8.14
Metoprolol8.70

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients < 50 Years Old Compared With Metoprolol in Transplant Recipients < 50 Years Old

(NCT01157234)
Timeframe: Change in Baseline, Month-12

Interventionpercent change (Least Squares Mean)
Nebivolol < 50 Years Old51.55
Metoprolol <50 Years Old-16.64

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients <50 Years Old Compared With Metoprolol in Transplant Recipients >/= 50 Years Old.

(NCT01157234)
Timeframe: Baseline and Month-12

Interventionpercent change (Least Squares Mean)
Nebivolol <50 Year Old51.55
Metoprolol >/= 50 Year Old-17.99

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients >/= 50 Years Old Compared With Metoprolol in Transplant Recipients Age >/= 50 Years Old.

(NCT01157234)
Timeframe: Change in Baseline, Month-12

Interventionpercent change (Least Squares Mean)
Nebivolol >/=50 Years Old-15.25
Metoprolol >/=50 Years Old-17.99

Percent Change in Plasma Nitric Oxide Level From Baseline to Month-twelve of Treatment With Nebivolol in Transplant Recipients >/= 50 Years Old Compared With Nebivolol in Transplant Recipients < 50 Years Old.

(NCT01157234)
Timeframe: Change in Baseline, Month-12

Interventionpercent change (Least Squares Mean)
Nebivolol >/=50 Years Old-15.25
Metoprolol <50 Years Old-16.64

Plasma Nitric Oxide Level (Nmol/L) at Month-12 Between the Groups.

(NCT01157234)
Timeframe: 12 Months

Interventionnmol/L (Least Squares Mean)
Nebivolol50.07
Metoprolol38.13

Plasma Nitric Oxide Level Change From Baseline to Month 12 Between the Groups.

Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L. (NCT01157234)
Timeframe: Change in Baseline, Month-12

Interventionpercent change (Least Squares Mean)
Nebivolol11.47
Metoprolol-17.27

Systolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 of Treatment Between the Groups

Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level (NCT01157234)
Timeframe: Change in Baseline, Month-12

Interventionmillimeter, Mercury (Least Squares Mean)
Nebivolol-2.65
Metoprolol-3.88

Cytokines Evaluation

Cd106(VCAM-1) , IP-10/CXCL10, MIG/CXCL9, MCP-1/CCL2, IL-1, RANTES, IL-8, IL12p70, TNF, IL-10, IL-6, IL-1, VEGF, FGF, CD54(ICAM-1) were analysed in urine 90 days after transplant (before randomization), and 365 days after transplant. Material were conserved at -80 Celsius, and analysed by ELISA at same time. Data was shown in MFI units (NCT01239472)
Timeframe: Urine and biopsy data are collected 90 days and 365 days after transplant.

,
InterventionMFI (Median)
IP10 90daysIP10 365daysMCP1 90daysMCP1 365daysMIG 90daysMIG 365daysRANTES 90daysRANTES 365daysIL8 90daysIL8 365daysIL12 90daysIL12 365daysTNF 90daysTNF 365daysIL10 90daysIL10 365 daysIL6 90daysIL6 365daysIL1 90daysIL1 365daysVEGF 90daysVEGF 365daysFGF 90daysFGF 365daysCD106 90daysCD106 365daysCD54 90daysCD54 365days
Everolimus8931474119137543358014515562443512412414615716418234926221522870454329285641961412931664
Tacrolimus380763234913063962871481444956411161241361531551792822812122288284393043222183241512696

Evaluation of Renal Function

Evaluation of renal function (serum creatinine) 90 days after transplant and 365 days after transplant. (NCT01239472)
Timeframe: 90 days after transplant and 365 days after transplant

,
Interventionmg/dL (Median)
Cr 90daysCr 365days
Everolimus1.31.4
Tacrolimus1.61.4

Reviews

1 review available for nitrates and Chronic Kidney Failure

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016

Trials

9 trials available for nitrates and Chronic Kidney Failure

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Changes in oxidative stress in renal graft patients receiving calcineurin inhibitors: cyclosporine versus tacrolimus.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2012, Volume: 10, Issue:5

    Topics: Adult; Antioxidants; Ascorbic Acid; Calcineurin Inhibitors; Cyclosporine; Enzyme Inhibitors; Female;

2012
Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease.
    Blood purification, 2002, Volume: 20, Issue:5

    Topics: Arginine; Blood Pressure; Cardiovascular Diseases; Female; Humans; Hypertension; Kidney Failure, Chr

2002
Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure.
    Kidney international, 2002, Volume: 62, Issue:4

    Topics: Administration, Oral; Adolescent; Arginine; Arteriosclerosis; Child; Cross-Over Studies; Dietary Sup

2002
Impairment of vascular responses to reactive hyperemia and nitric oxide in chronic renal failure.
    Nephron, 2002, Volume: 92, Issue:3

    Topics: Blood Pressure; Creatinine; Cysteine; Endothelium, Vascular; Female; Glutathione; Homocysteine; Huma

2002
Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure.
    Kidney international, 1999, Volume: 56, Issue:2

    Topics: Adolescent; Adult; Amino Acids; Arginine; Cyclic GMP; Double-Blind Method; Female; Glomerular Filtra

1999
Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?
    Circulation, 2000, Aug-22, Volume: 102, Issue:8

    Topics: Aged; Brachial Artery; Double-Blind Method; Endothelium, Vascular; Erythrocytes; Female; Folic Acid;

2000
Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:7

    Topics: Adult; Aged; Blood Platelets; Blood Pressure; Diastole; Enzyme Inhibitors; Humans; Hypotension; Kidn

2001
[Distribution of electrolytes and substances normally contained in urine in the extracellular space under dialysis].
    Klinische Wochenschrift, 1968, Nov-01, Volume: 46, Issue:21

    Topics: Ascitic Fluid; Creatinine; Electrolytes; Extracellular Space; Humans; Kidney Failure, Chronic; Nitra

1968

Other Studies

36 other studies available for nitrates and Chronic Kidney Failure

ArticleYear
"Removal of nitrate and nitrite by hemodialysis in end-stage renal disease and by sustained low-efficiency dialysis in acute kidney injury".
    Nitric oxide : biology and chemistry, 2020, 05-01, Volume: 98

    Topics: Acute Kidney Injury; Adult; Child; Cross-Sectional Studies; Female; Humans; Kidney Failure, Chronic;

2020
Using GIS Mapping to Track Hot Spots of Kidney Disease in California.
    The New England journal of medicine, 2020, 06-04, Volume: 382, Issue:23

    Topics: California; Geographic Information Systems; Geography, Medical; Groundwater; Humans; Kidney Failure,

2020
Diosgenin improves vascular function by increasing aortic eNOS expression, normalize dyslipidemia and ACE activity in chronic renal failure rats.
    Molecular and cellular biochemistry, 2013, Volume: 384, Issue:1-2

    Topics: Animals; Antioxidants; Aorta; Diosgenin; Dyslipidemias; Endothelium, Vascular; Glutathione; Kidney;

2013
Breath analysis in patients with end-stage renal disease: effect of haemodialysis.
    European journal of clinical investigation, 2008, Volume: 38, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Ammonia; Biomarkers; Breath Tests; Case-Control Studies; Female; Hum

2008
Elevation of serum apelin-13 is positively correlated with ADMA in patients on maintenance hemodialysis.
    Clinical nephrology, 2009, Volume: 71, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Arginine; Biomarkers; Female; Humans; Intercellular Signaling Peptid

2009
Endothelin-1, big endothelin-1, and nitric oxide in patients with chronic renal disease and hypertension.
    Journal of clinical laboratory analysis, 2009, Volume: 23, Issue:6

    Topics: Adult; Endothelin-1; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Nitra

2009
Appetite-regulating hormones in chronic kidney disease patients.
    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2011, Volume: 21, Issue:4

    Topics: Adolescent; Adult; Aged; Appetite; Body Mass Index; Cross-Sectional Studies; Enzyme-Linked Immunosor

2011
Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis.
    Kidney international, 2002, Volume: 62, Issue:2

    Topics: Animals; Antibodies; Arginine; Autoantibodies; Blood Urea Nitrogen; Creatinine; Glomerulonephritis;

2002
Association of renal injury with nitric oxide deficiency in aged SHR: prevention by hypertension control with AT1 blockade.
    Kidney international, 2002, Volume: 62, Issue:3

    Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterioles; Hypertension,

2002
Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure.
    Nitric oxide : biology and chemistry, 2003, Volume: 8, Issue:1

    Topics: Animals; Arginine; Blood Pressure; Creatine; Dietary Supplements; Disease Models, Animal; Glomerulos

2003
Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease.
    Kidney international, 2003, Volume: 64, Issue:4

    Topics: Adult; Arginine; Arteries; Endothelium, Vascular; Female; Humans; Hypertension; Kidney Failure, Chro

2003
Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis.
    Italian heart journal : official journal of the Italian Federation of Cardiology, 2004, Volume: 5, Issue:5

    Topics: Adult; Aged; Biomarkers; Blood Pressure; Cyclic GMP; Diastole; Endothelium, Vascular; Female; Homocy

2004
Evidence for generation of the precarcinogen nitrosodimethylamine in the small intestine in chronic renal failure.
    Kidney international. Supplement, 1983, Volume: 16

    Topics: Bacteria; Cocarcinogenesis; Dimethylnitrosamine; Duodenum; Gastric Mucosa; Humans; Kidney Failure, C

1983
Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production.
    Kidney international, 1995, Volume: 47, Issue:6

    Topics: Administration, Oral; Animals; Arginine; Blood Pressure; Captopril; Creatinine; Female; Kidney Failu

1995
Peritoneal nitric oxide is a marker of peritonitis in patients on continuous ambulatory peritoneal dialysis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1996, Volume: 11, Issue:12

    Topics: Acinetobacter Infections; Adult; Aged; Biomarkers; Dialysis Solutions; Female; Humans; Kidney Failur

1996
Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF).
    The Journal of clinical investigation, 1997, Feb-01, Volume: 99, Issue:3

    Topics: Angiotensin II; Animals; Aorta; Arginine; Blood Pressure; Brain; Creatinine; Enzyme Inhibitors; Gene

1997
Clinical evidence of peroxynitrite formation in chronic renal failure patients with septic shock.
    Free radical biology & medicine, 1997, Volume: 22, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Female; Free Radicals; Humans; Kidney Failure,

1997
Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans.
    Biochemical and biophysical research communications, 1998, Apr-07, Volume: 245, Issue:1

    Topics: Adult; Aged; Alleles; Coronary Disease; Female; Genetic Markers; Genotype; Humans; Kidney Failure, C

1998
Enhanced production of nitric oxide may be involved in acute hypotension during maintenance hemodialysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1998, Volume: 31, Issue:5

    Topics: Acute Disease; Anions; Blood Pressure; Cyclic GMP; Endothelin-1; Female; Heart Rate; Humans; Hypoten

1998
Increased excretion of nitric oxide in exhaled air of patients with chronic renal failure.
    Clinical science (London, England : 1979), 1999, Volume: 96, Issue:1

    Topics: Analysis of Variance; Atrial Natriuretic Factor; Breath Tests; Chi-Square Distribution; Cyclic GMP;

1999
Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis.
    The American journal of physiology, 1999, Volume: 276, Issue:5

    Topics: Adult; Aged; Arginine; Citrulline; Creatinine; Cyclic GMP; Female; Humans; Hypertension, Renal; Kidn

1999
Nitric oxide metabolites in decompensated liver cirrhosis.
    Digestive diseases and sciences, 1999, Volume: 44, Issue:7

    Topics: Adult; Aged; Angina Pectoris; Female; Hemoglobins; Humans; Kidney Failure, Chronic; Liver Cirrhosis;

1999
Increased plasma adrenomedullin levels in hemodialysis patients with sustained hypotension.
    Kidney international, 2000, Volume: 57, Issue:2

    Topics: Adrenomedullin; Adult; Blood Pressure; Blood Volume; Female; Humans; Hypotension; Interleukin-1; Iod

2000
Role of nitric oxide in haemodialysis hypotension.
    Acta physiologica Scandinavica, 2000, Volume: 168, Issue:1

    Topics: Adult; Aged; Blood Pressure; Female; Humans; Hypotension; Kidney Failure, Chronic; Male; Middle Aged

2000
Biphasic changes in nitric oxide generation in hemodialyzed patients with end-stage renal disease treated with recombinant human erythropoietin.
    The American journal of the medical sciences, 2000, Volume: 319, Issue:3

    Topics: Blood Pressure; Body Weight; Erythropoietin; Female; Heart Rate; Humans; Kidney Failure, Chronic; Ma

2000
Erythropoietin does not affect nitric oxide system in rats with chronic renal failure.
    Journal of Korean medical science, 2000, Volume: 15, Issue:2

    Topics: Acetylcholine; Anemia; Animals; Aorta, Thoracic; Body Weight; Erythropoietin; Hypertension, Renal; I

2000
Effect of hemodialysis on plasma nitric oxide levels.
    Artificial organs, 2000, Volume: 24, Issue:5

    Topics: Colorimetry; Cyclic GMP; Female; Follow-Up Studies; Humans; Inflammation Mediators; Kidney Failure,

2000
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.
    Kidney international, 2000, Volume: 58, Issue:2

    Topics: Adenoviridae; Animals; Blood Pressure; Blood Urea Nitrogen; Cardiomegaly; Cyclic GMP; Fibrosis; Gene

2000
Temporal changes of cytokines and nitric oxide products in urine from renal transplant patients.
    Kidney international, 2000, Volume: 58, Issue:2

    Topics: Acute Disease; Adult; Creatinine; Cyclic GMP; Cytokines; Female; Follow-Up Studies; Graft Rejection;

2000
Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients.
    Cardiovascular research, 2000, Aug-18, Volume: 47, Issue:3

    Topics: Aged; Analysis of Variance; Antioxidants; Ascorbic Acid; Cardiovascular Diseases; Case-Control Studi

2000
Total nitric oxide production is low in patients with chronic renal disease.
    Kidney international, 2000, Volume: 58, Issue:3

    Topics: Adult; Aged; Arginine; Blood Pressure; Creatinine; Female; Humans; Hypertension, Renal; Kidney Failu

2000
Decreased nitric oxide synthesis in rats with chronic renal failure.
    Journal of Korean medical science, 2000, Volume: 15, Issue:4

    Topics: Animals; Aorta, Thoracic; Enzyme Induction; Isoenzymes; Kidney; Kidney Failure, Chronic; Male; Nephr

2000
Reversible sequestration of nitric oxide by hemoglobin during hemodialysis in end-stage renal disease.
    The American journal of the medical sciences, 2001, Volume: 321, Issue:2

    Topics: Anemia; Arginine; Erythropoietin; Hematocrit; Hemoglobins; Humans; Hypotension; Kidney Failure, Chro

2001
Urinary excretion of vasoactive substances in chronic renal failure.
    Clinical nephrology, 2001, Volume: 55, Issue:5

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Creatinine; Cyclic GMP; Endothelin-1; Female; Humans; Kid

2001
Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency.
    Hypertension (Dallas, Tex. : 1979), 2002, Volume: 39, Issue:1

    Topics: alpha-Tocopherol; Animals; Antioxidants; Arginine; Creatinine; Endothelium, Vascular; Kidney Failure

2002
The evaluation of oxidative stress in patients with chronic renal failure.
    Clinica chimica acta; international journal of clinical chemistry, 2002, Volume: 322, Issue:1-2

    Topics: Adult; Blood Urea Nitrogen; Creatinine; Dialysis; Female; Humans; Kidney Failure, Chronic; Male; Mal

2002